Sowell Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sowell Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-487	Closed	-$38K	–	802
2021 Q1	$38K	Buy	487 +69	+17%	+$5.64K	﹤0.01%	1767
2020 Q4	$37K	Buy	418 +122	+41%	+$9.67K	﹤0.01%	1507
2020 Q3	$23K	Sell	296 -27	-8%	-$2.73K	﹤0.01%	1493
2020 Q2	$40K	Sell	323 -9	-3%	-$894	﹤0.01%	1228
2020 Q1	$28K	Buy	332 +89	+37%	+$7.67K	﹤0.01%	1264
2019 Q4	$21K	Sell	243 -48	-16%	-$3.63K	﹤0.01%	1413
2019 Q3	$20K	Buy	+291	New	+$22.4K	﹤0.01%	1273

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sowell Financial Services's BMRN Position: Q2 2021 in Review

Sowell Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 487 shares — an estimated $38K sold.

Sowell Financial Services first reported a position in BMRN in Q3 2019 and held it in 7 quarters. The position peaked at $40K in Q2 2020. 531 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

Sowell Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Sowell Financial Services sold 487 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $38K.
Sowell Financial Services first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 7 quarters.
Sowell Financial Services's BioMarin Pharmaceuticals position peaked at $40K in Q2 2020.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.